BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tai CJ, Huang MT, Wu CH, Wang CK, Tai CJ, Chang CC, Hsieh CI, Chang YJ, Wu CJ, Kuo LJ, Wei PL, Chen RJ, Chiou HY. Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma. Medicine (Baltimore) 2016;95:e3259. [PMID: 27082562 DOI: 10.1097/MD.0000000000003259] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ji F, Fu SJ, Guo ZY, Pang H, Ju WQ, Wang DP, Hua YP, He XS. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2016;95:e4065. [PMID: 27399091 DOI: 10.1097/MD.0000000000004065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
2 Lv Y, Xu M, Sun Y, Liu Y, Zhao L, Liu X, Li Z, Shi G, Jia J, Bi L, Ma N, Zhang X, Qi C. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2021;100:e26850. [PMID: 34414935 DOI: 10.1097/MD.0000000000026850] [Reference Citation Analysis]
3 Chen H, Huang S, Wang H, Chen X, Zhang H, Xu Y, Fan W, Pan Y, Wen Q, Lin Z, Wang X, Gu Y, Ding B, Chen J, Wu X. Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models. Drug Deliv 2021;28:1067-79. [PMID: 34109887 DOI: 10.1080/10717544.2021.1921078] [Reference Citation Analysis]
4 Langdon CG, Platt JT, Means RE, Iyidogan P, Mamillapalli R, Klein M, Held MA, Lee JW, Koo JS, Hatzis C, Hochster HS, Stern DF. Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Mol Cancer Ther 2017;16:1041-53. [PMID: 28292938 DOI: 10.1158/1535-7163.MCT-16-0794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
5 Sheng W, Geng J, Li L, Shang Y, Jiang M, Zhen Y. An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation. Oncol Rep 2020;43:851-63. [PMID: 32020213 DOI: 10.3892/or.2020.7468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget 2018;9:21613-27. [PMID: 29765563 DOI: 10.18632/oncotarget.25085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
7 Hajatdoost L, Sedaghat K, Walker EJ, Thomas J, Kosari S. Chemotherapy in Pancreatic Cancer: A Systematic Review. Medicina (Kaunas). 2018;54:48. [PMID: 30344279 DOI: 10.3390/medicina54030048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
8 Arias-Pinilla GA, Modjtahedi H. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel) 2021;13:1781. [PMID: 33917882 DOI: 10.3390/cancers13081781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]